The burgeoning field of obesity management has witnessed remarkable advancements with the emergence of dual GLP-3 receptor agonists, notably Retatrutide and Trizepatide. These novel therapies represent a significant https://hassanzbxd111584.eveowiki.com/2010890/glp_3_receptor_agonists_retatrutide_trizepatide